Champions Oncology, Inc. (CSBR)

Champions Oncology's stock has experienced volatility over the past six months, with a 52-week range between $5.59 and $11.98, and has decreased approximately 39.20% over the last year. In Q1 Fiscal 2026, the company reported record revenue but a wider-than-anticipated operating loss due to increased costs and a compressed gross margin. In Q2 Fiscal 2026, Champions Oncology reported increased revenue and net income, beating analysts' expectations, with improved oncology services margin, but year-to-date adjusted EBITDA decreased due to increased R&D and administrative expenses.

Seeking Alpha displays mean and median monthly returns for CSBR to identify seasonal patterns, but access to this specific data requires a free account. Therefore, specific details regarding the demand seasonality for Champions Oncology, Inc.'s products and services are not readily available in the provided search results.

Champions Oncology, Inc. is a technology-enabled research company focused on accelerating drug discovery and development in oncology. The company operates within the Pharmaceuticals & Biotech sector and the Life Sciences Tools and Services industry. Its core offerings include a Tumorgraft Technology Platform for personalized cancer care and translational research, Lumin Bioinformatics for oncology data-driven insights, and preclinical and clinical research services to support oncology drug development.

Champions Oncology has a specialized geographic footprint with operational centers in Hackensack, New Jersey (Corporate Headquarters), Rockville, Maryland (Research Operations), Ramat Gan, Israel (Bioinformatics & Computational Biology), and Bresso, Italy (Clinical Specialty Testing Lab). The company contracts with pharmaceutical and biotechnology companies across North America, Europe, and Asia.

Champions Oncology aims to establish a global leadership position in oncology research and cultivate a solid reputation for the quality of its data acquisition and interpretation. The company emphasizes scientific excellence, teamwork, integrity, and respect in its mission and values. No specific events negatively affecting Champions Oncology, Inc.'s brand reputation in the past year were found in the provided search results.

Champions Oncology has a mixed ownership structure. Institutional investors hold approximately 35.23% to 37.52% of the stock, insiders own 14.82%, and public companies and individual investors hold the remaining shares, ranging from 2.28% to 47.66%. Major institutional owners include Battery Management Corp., NEA Management Company, LLC, Vanguard Group Inc, Tocqueville Asset Management L.p., Morgan Stanley, Renaissance Technologies Llc, BlackRock, Inc., and Geode Capital Management, Llc.